Le Lézard
Classified in: Science and technology, Business
Subjects: CCA, FVT

Remark Holdings Sets Fourth Quarter and Full Year 2017 Earnings Call for Thursday, March 29, 2018 at 4:30 p.m. ET


LAS VEGAS, March 16, 2018 /PRNewswire/ -- Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence (AI) solutions and digital media properties, including Vegas.com, will hold a conference call on Thursday, March 29, 2018 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its results for the fourth quarter and full year ended December 31, 2017. Financial results will be issued in a press release prior to the call.

Remark Holdings' Chairman and CEO Kai-Shing Tao and CFO Douglas Osrow will host the conference call, followed by a question and answer period.

Please call the conference telephone number 10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 949-574-3860.

Date: Thursday, March 29, 2018
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-Free Number: 888-882-4478
International Number: 323-701-0225
Conference ID:  5682880

The conference call will be broadcast simultaneously and available for replay via the Investors section of the company's website here.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through April 2, 2018.

Toll-Free Replay Number: 844-512-2921
International Replay Number: 412-317-6671
Replay ID: 5682880

Remark Holdings, Inc. (PRNewsFoto/Remark Media, Inc.)

About Remark Holdings, Inc.
Remark Holdings, Inc. (NASDAQ: MARK) primarily focuses on the development and deployment of artificial-intelligence-based solutions for businesses in many industries. Additionally, the company owns and operates digital media properties that deliver relevant, dynamic content. The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Chengdu and Hangzhou, China. For more information, please visit the company's website at www.remarkholdings.com.

Company Contact:
Douglas Osrow, CFO
Remark Holdings, Inc.
[email protected] 
702-701-9514, ext. 3025

Investor Relations Contact:
Matt Glover or Tom Colton
Liolios Group, Inc.
[email protected] 
949-574-3860

 

SOURCE Remark Holdings, Inc.


These press releases may also interest you

at 07:05
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
MindMed to Present at Upcoming May Medical Conferences
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Firms in France Seek to Squeeze More Value From Salesforce
Enterprises in France, seeking better returns on investment, are turning to service providers that can manage their Salesforce platforms more efficiently, according to a new research report published today by Information Services Group (ISG) , a...

at 07:05
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...

More news about Science and technology...


News published on and distributed by: